A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
1 other identifier
interventional
90
1 country
2
Brief Summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started May 2026
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 11, 2026
CompletedFirst Submitted
Initial submission to the registry
June 11, 2026
CompletedFirst Posted
Study publicly available on registry
June 16, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
June 17, 2026
June 1, 2026
10 months
June 11, 2026
June 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage change in body weight from baseline
Week 26
Study Arms (4)
Placebo group
PLACEBO COMPARATORPlacebo
CX11 Group A
EXPERIMENTALCX11 Group B
EXPERIMENTALCX11 Group C
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Male or female, 18-55 years.
- BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
- Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
- Able to comply with study procedures and reproductive requirements.
You may not qualify if:
- Diabetes or obesity due to endocrine/genetic causes.
- Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
- Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
- Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
- Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Corxel Investigational site
Las Vegas, Nevada, 89113, United States
Corxel Investigational Site
Austin, Texas, 78744, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 11, 2026
First Posted
June 16, 2026
Study Start
May 11, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
June 17, 2026
Record last verified: 2026-06